– USA, CA – Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, today announced the appointment of Susanne Meline to its Board of Directors, effective January 31, 2021, bringing the Board to seven members.
“We are excited to have a shareholder with Susanne’s small cap company experience join our Board,” said Board Chairman, Martin Colombatto. “She has served as an observer in our Board meetings over the past three months and we have come to value her insights and broad perspective. We welcome her as a member of our board.”
About Susanne Meline
Ms. Meline has an extensive background in finance, law, and corporate governance with more than 20 years of experience advising corporate clients and their boards. In 2003, Ms. Meline co-founded investment advisor Francis Capital Management, where she serves as the firm’s special situations advisor. FCM is a current Ra Medical shareholder.
Before Francis Capital Management, Ms. Meline was an investment banker with Houlihan Lokey, a global investment bank serving corporations, institutions, and governments. She also was an attorney in the corporate group of Jones Day, an international law firm. Ms. Meline is a Certified Director through the UCLA Anderson School of Management, a Board Leadership Fellow for the National Association of Corporate Directors, and holds a CERT Certificate in Cybersecurity Oversight from the NACD and Carnegie Mellon University Software Engineering Institute. Ms. Meline writes about corporate governance topics as a Select Contributor for the Small Cap Institute and, as a Pioneer Member of the Athena Alliance, guides current and aspiring board directors regarding financing small-cap companies.
She currently serves as the Lead Independent Director and Audit Chair of the publicly traded ClearSign Technologies Corporation, and previously served on the Boards of Aqua Metals, Inc. and Finomial Corporation.
“I see a significant opportunity at Ra Medical and welcome the opportunity to take a more active role as a member of the board,” said Ms. Meline. “I look forward to making contributions that further support progress in generating shareholder value and improving patients’ lives.”
Ms. Meline received a B. A from the University of California, Los Angeles, and a J.D. from the University of California, Hastings College of the Law.
About Ra Medical Systems
Ra Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases. In May 2017 the DABRA excimer laser system received FDA 510(k) clearance in the U.S. for crossing chronic total occlusions, or CTOs, in patients with symptomatic infrainguinal lower extremity vascular disease with the intended use for ablating a channel in occlusive peripheral vascular disease. The Pharos excimer laser system is FDA-cleared and is used as a tool in the treatment of psoriasis, vitiligo, atopic dermatitis, and leukoderma. DABRA and Pharos are both based on Ra Medical’s core excimer laser technology platform and deploy similar mechanisms of action. Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, Calif. The vertically integrated facility is ISO 13485 certified and is licensed by the State of California to manufacture sterile, single-use catheters in controlled environments.
For more information: https://www.ramed.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.